Condensed Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 51,406	$ 51,101	$ 153,922	$ 120,043
Gross profit	3,739	15,853	9,190	33,511
General and administrative expenses	12,665	20,122	49,030	49,618
Sales and marketing expenses	10,000	16,974	40,709	39,161
Research and development expenses	921	2,315	2,831	4,891
Stock-based compensation expenses	8,080	8,644	23,404	22,303
Depreciation and amortization expenses	3,425	3,200	10,353	7,457
Impairment of assets			58,210
Acquisition-related expenses (income), net		(13,454)		(6,566)
Loss from equity method investments	1,420	1,837	4,495	1,837
Operating loss	(32,772)	(23,785)	(179,842)	(85,190)
Foreign exchange (gain) loss, net	(9,319)	2,585	5,424	1,153
Change in fair value of warrant liability	(31,913)		51,275
Interest expenses, net	10,437	8,680	30,147	26,005
Finance income from ABG		(210)		(557)
Other expense (income), net	(38)	(1,116)	4,944	(6,185)
Loss before income taxes	(1,939)	(33,724)	(271,632)	(105,606)
Deferred income tax expenses (recoveries)	134	2,432	(4,013)	(3,987)
Current income tax expenses (benefit)	243	195	505	402
Net loss	$ (2,316)	$ (36,351)	$ (268,124)	$ (102,021)
Net loss per share - basic and diluted	$ (0.02)	$ (0.37)	$ (2.23)	$ (1.05)
Weighted average shares used in computation of net loss per share - basic and diluted	129,100,909	98,130,507	120,128,856	96,742,626
Net loss	$ (2,316)	$ (36,351)	$ (268,124)	$ (102,021)
Foreign currency translation gain (loss), net	2,265	(4,863)	(7,184)	(2,414)
Unrealized gain on available-for-sale debt securities	193	11	154	80
Other comprehensive income (loss)	2,458	(4,852)	(7,030)	(2,334)
Comprehensive income (loss)	142	(41,203)	(275,154)	(104,355)
Product Costs [Member]
Cost of sales	34,224	35,047	108,616	85,806
Inventory Valuation Adjustments [Member]
Cost of sales	$ 13,443	$ 201	$ 36,116	$ 726